The US FDA’s Real-Time Oncology Review (RTOR) program is changing the pace of oncology regulatory review, with approximately one in five oncology approvals now coming through this pathway. By giving the FDA access to key clinical data before the complete application is submitted, RTOR can shorten the time between pivotal trial results and regulatory review, but it also places greater demands on how quickly sponsors and CROs can prepare data and documentation for review.

From an operational perspective, RTOR does not fundamentally change how a clinical trial is run. Rather, it changes the pace at which it needs to be run.

Read our commentary on what RTOR means in practice, and how sponsors and CROs can prepare for the faster pace of execution it demands.

Unlock the PDF

Enter your details below to read the full article or download a PDF version.

* indicates required fields

"*" indicates required fields

This field is for validation purposes and should be left unchanged.